Home / Market News / $JNJ
benzinga Corporate Catalyst Impact 55/100 ● positive

Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $287

Oct 16, 2026, 4:07 PM UTC · Primary ticker $JNJ

Wells Fargo analyst Larry Biegelsen reiterated an Overweight rating on Johnson & Johnson and increased the price target from $275 to $287. This indicates a positive outlook on J&J's future performance and could lead to increased investor confidence.

Wells Fargo analyst Larry Biegelsen has maintained an 'Overweight' rating on Johnson & Johnson (JNJ) and raised the price target from $275 to $287. This action signals continued confidence from a major financial institution in J&J's business prospects and valuation. The increased price target suggests that the analyst believes J&J's stock has more upside potential than previously estimated, likely due to factors such as strong product pipelines, market positioning, or financial performance. This news is primarily positive for JNJ shareholders, potentially leading to a short-term boost in stock price as investors react to the upgraded outlook. In the long term, sustained analyst confidence can contribute to a more stable and upward trajectory for the stock, though it's important to note that analyst ratings are just one factor in a complex market. A key opportunity for traders is to consider this as a bullish signal, while a risk could be that the market has already priced in such expectations or that other unforeseen factors could impact J&J's performance.

$JNJ positive Analyst price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.